Netmore and Alliot Technologies Announce Partnership to Deliver End-to-End IoT Solutions
19.3.2025 08:00:00 CET | Business Wire | Press Release
Netmore Group, a leading global operator of IoT networks, announced today a partnership with Alliot Technologies, a specialist IoT solutions provider serving the UK and European markets. This collaboration will be officially unveiled at Channel Live 2025, one of the UK's premier events for the tech and telecom industries, taking place at the NEC in Birmingham on March 19-20, 2025.
The partnership brings together the strengths of two leading companies, including Netmore’s expertise in designing, deploying, and operating IoT networks for low power wide area devices and sensors, and Alliot’s proven capabilities in system design, supply, and deployment of IoT business solutions. Together, the companies will deliver a full complement of solutions pre-provisioned to operate with Netmore’s public and local connectivity services, allowing solution providers and enterprise customers to immediately drive efficiencies through automation, reduce operational costs, and support energy savings and sustainability programs.
“Long-range networks and low-cost, low-power devices are becoming ubiquitous in enterprise, utility, and smart city applications,” said Vadim Lyu, UK Managing Director at Netmore. “With fewer steps required to deploy an end-to-end solution and value-added services built into the procurement processes, our partnership with Alliot is an example of how the IoT ecosystem has matured to provide tangible cost and time-saving benefits to customers ready to deploy solutions today.”
From proof-of-concept kits to large, full scale commercial deployments and bespoke product design, Alliot Technologies is committed to delivering innovative IoT solutions that empower integrators and service providers across industries.
Craig Herrett, Managing Director of Alliot Technologies, stated, "This partnership marks a significant step forward in our mission to make advanced IoT technology more accessible and user-friendly for new solutions integrators and resellers. Whilst we offer private servers, there are capex costs associated with this, both from setup and maintenance, not to mention the required knowledge in running LoRaWAN servers and networks. We see this partnership with Netmore as a real enabler for service providers and resellers without those capex costs and without the need for an IT team to run the infrastructure.”
The partnership will be showcased at Channel Live 2025, where Netmore and Alliot will be demonstrating their offerings in Stand B60. Graeme Boyle, Business Development Manager at Netmore Group UK will also be presenting in a session titled “Delivering Mobile Connectivity Solutions” on Wednesday, March 19th from 15:55-16:30.
About Netmore Group
Netmore Group is an IoT network operator, building the leading multinational network to advance sustainable business practices. We offer a reliable network platform and leading connectivity expertise for efficient measuring, monitoring, and optimisation of resource use. With 10 years in the industry, we have a solid track record, operating borderless on the European market and have grown to become a leading global network operator. Netmore group’s main owner is the Nordic infrastructure investor Polar Structure.
About AllIot:
Alliot Technologies is Europe’s leading distributor of IoT products. Specialising in LoRaWAN and cellular IoT (NB-IoT & LTE-M), Alliot provides easy access to the best-in-class hardware, services and support to customers throughout the UK and Europe. Alliot’s vision is to simplify the set-up and ongoing management of IoT devices by providing solutions ready to be interfaced with the users’ selected IT structure through device provisioning services and support from an expert technical team.
Alliot makes IoT accessible to all, helping partners to develop their solutions from proof of concept to fully scalable commercial solutions, enabling them to take the specific piece they need to bring their projects to life.
For more information, contact Alliot Technologies at contact@alliot.co.uk or visit https://alliot.co.uk/
LoRaWAN® is a mark used under license from the LoRa Alliance®
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305772585/en/
Contacts
Media Contacts
James Gerber
+1 617-863-0856
Crackle Communications
netmore@cracklepr.com
Netmore Contact:
Ken Lynch
VP, Global Marketing
+1 617-877-5393
ken.lynch@netmoregroup.com
Alliot Contact:
Hossam Hassan
Marketing Executive
+44 1484 599544
hossam.hassan@alliot.co.uk
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom